Amphastar Pharmaceuticals, Inc. Accounts Receivable
Amphastar Pharmaceuticals, Inc. (AMPH) had Accounts Receivable of $144.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $144.86M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $147.85M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $143.56M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $146.81M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $144.86M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $147.85M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $143.56M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $146.81M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $132.98M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $144.64M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $136.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | $139.63M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $131.41M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $138.11M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $114.94M 10-K · filed 2025-03-03 |
| 2023-09-30 | $118.99M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $104.72M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $100.64M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $88.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $77.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $80.81M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $73.17M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $78.80M 10-K · filed 2023-03-01 |
| 2021-09-30 | $78.09M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $67.89M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $77.94M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $66.00M 10-K · filed 2022-03-11 |
| 2020-09-30 | $52.38M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $49.86M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $57.78M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $45.38M 10-K · filed 2021-03-15 |
| 2019-09-30 | $45.26M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $48.82M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $54.93M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $52.16M 10-K · filed 2020-03-16 |
| 2018-09-30 | $43.82M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $41.28M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $31.88M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $36.00M 10-K · filed 2019-03-15 |
| 2017-09-30 | $24.15M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $24.12M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $25.89M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $26.78M 10-K · filed 2018-03-14 |
| 2016-09-30 | $26.55M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $23.13M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $23.08M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $33.23M 10-K · filed 2017-03-15 |
| 2015-09-30 | $25.00M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $19.83M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $21.65M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $22.85M 10-K · filed 2016-03-15 |
| 2014-09-30 | $26.60M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $18.60M 10-Q · filed 2014-08-13 |
| 2013-12-31 | $24.59M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |